Anti-Hypertensives Market to 2017 - Patent Expiries of Blockbusters such as Diovan, Micardis, Avapro and Atacand to Accelerate Erosion


March 23, 2012
119 Pages - SKU: XGBR3817528
License type:
Table of Contents Search inside this report Related Reports Detailed Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Global Anti-Hypertensives Market - Introduction
2.1 GBI Research Report Guidance
3 Global Anti-Hypertensives Market - Market Overview
3.1 Introduction
3.2 Revenue Forecasts for the Global Anti-Hypertensives Market
3.2.1 Revenue
3.2.2 Annual Cost of Therapy
3.2.3 Treatment Usage Patterns
3.3 Anti-Hypertensives Market Drivers
3.3.1 Uptake of Fixed Dose Combination Therapies due to Better Efficacy in Hypertension and Pulmonary Arterial Hypertension
3.4 Anti-Hypertensives Market Restraints
3.4.1 Low Compliance in Hypertensive Patients
3.4.2 Patent Expiries of Major Blockbusters Including Diovan, Avapro, Blopress/Atacand, Cozaar/Hyzaar and Tracleer, Pose a Threat to Market Revenues
3.4.3 Low Treatment Seeking Behavior and Diagnosis in Pulmonary Arterial Hypertension
3.5 Generics Share in the Global Anti-Hypertensives Market
4 Global Anti-Hypertensives Market: Therapeutic Landscape
4.1 Hypertension
4.1.1 Introduction
4.1.2 Treatment Flow Algorithm for Hypertension
4.1.3 Revenue
4.1.4 Annual Cost of Therapy
4.1.5 Treatment Usage Patterns
4.1.6 Market Segmentation by Geography
4.2 Pulmonary Arterial Hypertension (PAH) Market
4.2.1 Introduction
4.2.2 Treatment Flow Algorithm for Pulmonary Arterial Hypertension
4.2.3 Revenue
4.2.4 Annual Cost of Therapy
4.2.5 Treatment Usage Patterns
4.2.6 Market Segmentation by Geography
5 Global Anti-Hypertensives Market - Geographical Landscape
5.1 Geographical Break-up
5.2 The US
5.2.1 Revenue
5.2.2 Annual Cost of Therapy
5.2.3 Treatment Usage Patterns
5.3 Top Five Countries in Europe
5.3.1 Revenue
5.3.2 Revenue by Country
5.3.3 Annual Cost of Therapy
5.3.4 Treatment Usage Patterns
5.4 Japan
5.4.1 Revenue
5.4.2 Annual Cost of Therapy
5.4.3 Treatment Usage Patterns
6 Global Anti-Hypertensives Market - Pipeline Analysis
6.1 Introduction
6.1.1 Research and Development Pipeline - Hypertension
6.1.2 Research and Development Pipeline - Pulmonary Arterial Hypertension
6.2 Profiles of Key Late-Stage Drugs in the Anti-Hypertension Market
6.2.1 SPP635
6.2.2 Pioglitazone
6.2.3 LCZ696
6.2.4 QT1571 (Imatinib)
6.2.5 Selexipag (NS-304, ACT-293987)
6.2.6 PS-433540 (DARA)
6.2.7 Macitentan (ACT-064992, Actelion 1)
6.2.8 Riociguat (BAY63-2521)
7 Global Anti-Hypertensives Market - Competitive Landscape
7.1 Market Share Analysis
7.2 Competitive Profiling
7.2.1 Novartis
7.2.2 Merck
7.2.3 Daiichi Sankyo
7.2.4 Sanofi
7.2.5 AstraZeneca
7.2.6 United Therapeutics
7.2.7 Actelion
7.2.8 Pfizer
8 Global Anti-Hypertensives Market - Strategic Consolidations
8.1 Overview
8.2 Deals by Type
8.2.1 M&A Deals by Indication
8.2.2 M&A Deals by Year
8.2.3 M&A Deals by Geography
8.2.4 Summary of Major M&A Deals
8.3 R&D Licensing Agreements
8.3.1 Licensing Agreements by Indication
8.3.2 Licensing Agreements by Phase
8.3.3 Licensing Agreements by Geography
8.3.4 Licensing Agreements for Drugs in Phase II and Phase III Stage
8.3.5 Licensing Agreements for Approved Drugs
9 Global Anti-Hypertensives Market - Appendix
9.1 Market Definitions
9.2 Abbreviations
9.3 Research Methodology
9.3.1 Coverage
9.3.2 Secondary Research
9.3.3 Primary Research
9.3.4 Therapeutic Landscape
9.3.5 Market Size by Geography
9.3.6 Geographical Landscape
9.3.7 Pipeline Analysis
9.3.8 Competitive Landscape
9.3.9 Expert Panel Validation
9.4 Contact Us
9.5 Disclaimer
9.6 Sources
1.1 List of Tables
Table 1: Anti-Hypertensives Market, Global, Revenue ($bn), 2002-2010
Table 2: Anti-Hypertensives Market, Global, Revenue Forecasts ($bn), 2010-2017
Table 3: Anti-Hypertensives Market, Global, Annual Cost of Therapy ($), 2002–2010
Table 4: Anti-Hypertensives Market, Global, Annual Cost of Therapy ($), 2010–2017
Table 5: Anti-Hypertensives Market, Global, Treatment Usage Patterns (millions), 2002–2010
Table 6: Anti-Hypertensives Market, Global, Treatment Usage Patterns (millions), 2010–2017
Table 7: Hypertension Therapeutics Market, Global, Revenue ($bn), 2002–2010
Table 8: Hypertension Therapeutics Market, Global, Revenue Forecasts ($bn), 2010–2017
Table 9: Hypertension Therapeutics Market, Global, Annual Cost of Therapy ($), 2002–2010
Table 10: Hypertension Therapeutics Market, Global, Annual Cost of Therapy ($), 2010-2017
Table 11: Hypertension Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002–2010
Table 12: Hypertension Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010–2017
Table 13: Hypertension Therapeutics Market, Global, Market Segmentation by Geography ($bn), 2002–2010
Table 14: Hypertension Therapeutics Market, Global, Market Segmentation by Geography ($bn), 2010–2017
Table 15: PAH Therapeutics Market, Global, Revenue ($m), 2002–2010
Table 16: PAH Therapeutics Market, Global, Revenue Forecasts ($m), 2010–2017
Table 17: PAH Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2010
Table 18: PAH Therapeutics Market, Global, Annual Cost of Therapy ($), 2010-2017
Table 19: PAH Therapeutics Market, Global, Treatment Usage Patterns (thousand), 2002–2010
Table 20: PAH Therapeutics Market, Global, Treatment Usage Patterns (thousand), 2010–2017
Table 21: PAH Therapeutics Market, Global, Market Segmentation by Geography ($m), 2002–2010
Table 22: PAH Therapeutics Market, Global, Market Segmentation by Geography ($m), 2010–2017
Table 23: Anti-Hypertensives Market, Global, Revenue by Geography ($bn), 2002–2010
Table 24: Anti-Hypertensives Market, Global, Revenue Forecasts by Geography ($bn), 2010–2017
Table 25: Anti-Hypertensives Market, The US, Revenue ($bn), 2002–2010
Table 26: Anti-Hypertensives Market, The US, Revenue Forecasts ($bn), 2010–2017
Table 27: Anti-Hypertensives Market, The US, Annual Cost of Therapy ($), 2002–2010
Table 28: Anti-Hypertensives Market, The US, Annual Cost of Therapy ($), 2010–2017
Table 29: Anti-Hypertensives Market, The US, Treatment Usage Patterns (millions), 2002–2010
Table 30: Anti-Hypertensives Market, The US, Treatment Usage Patterns (millions), 2010–2017
Table 31: Anti-Hypertensives Market, Top Five Countries in Europe, Revenue ($bn), 2002–2010
Table 32: Anti-Hypertensives Market, Top Five Countries in Europe, Revenue Forecasts ($bn), 2010–2017
Table 33: Anti-Hypertensives Market, Top Five Countries in Europe, Revenue by Country ($bn), 2002–2010
Table 34: Anti-Hypertensives Market, Top Five Countries in Europe, Revenue Forecasts by Country ($bn), 2010–2017
Table 35: Anti-Hypertensives Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2002–2010
Table 36: Anti-Hypertensives Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2010–2017
Table 37: Anti-Hypertensives Market, Top Five Countries in Europe, Treatment Usage Patterns (millions), 2002–2010
Table 38: Anti-Hypertensives Market, Top Five Countries in Europe, Treatment Usage Patterns (millions), 2010–2017
Table 39: Anti-Hypertensives Market, Japan, Revenue ($bn), 2002–2010
Table 40: Anti-Hypertensives Market, Japan, Revenue Forecasts ($bn), 2010–2017
Table 41: Anti-Hypertensives Market, Japan, Annual Cost of Therapy ($), 2002–2010
Table 42: Anti-Hypertensives Market, Japan, Annual Cost of Therapy ($), 2010–2017
Table 43: Anti-Hypertensives Market, Japan, Treatment Usage Patterns (millions), 2002–2010
Table 44: Anti-Hypertensives Market, Japan, Treatment Usage Patterns (millions), 2010–2017
Table 45: Anti-Hypertensives Market, Global, R&D Pipeline by Phase in Hypertension Market, July 2011
Table 46: Anti-Hypertensives Market, Global, R&D Pipeline by Phase in Pulmonary Arterial Hypertension Market, 2011
Table 47: Anti-Hypertensives Market, Global, Major M&A Deals, 2005–2011
Table 48: Anti-Hypertensives Market, Global, Licensing Agreements for Drugs in Phase II and Phase III Stage, 2005–2011
Table 49: Anti-Hypertensives Market, Global, Licensing Agreements for Approved Drugs, 2005–2011
1.2 List of Figures
Figure 1: Anti-Hypertensives Market, Global, Drivers and Restraints, 2011
Figure 2: Anti-Hypertensives Market, Global, Revenue Forecasts ($bn), 2002–2017
Figure 3: Anti-Hypertensives Market, Global, Annual Cost of Therapy ($), 2002–2017
Figure 4: Anti-Hypertensives Market, Global, Treatment Usage Patterns (millions), 2002–2017
Figure 5: Anti-Hypertensives Market, Global, Diseased Population (millions), 2002–2017
Figure 6: Anti-Hypertensives Market, Global, Treatment-Seeking Population (millions), 2002–2017
Figure 7: Anti-Hypertensives Market, Global, Diagnosed Population (millions), 2002–2017
Figure 8: Anti-Hypertensives Market, Global, Prescription Population (millions), 2002–2017
Figure 9: Anti-Hypertensives Market, Global, Branded versus Generic Market Share (%), 2010
Figure 10: Anti-Hypertensives Market, Treatment Flow Algorithm for Hypertension, 2011
Figure 11: Hypertension Therapeutics Market, Global, Revenue Forecasts ($bn), 2002–2017
Figure 12: Hypertension Therapeutics Market, Global, Annual Cost of Therapy ($), 2002–2017
Figure 13: Hypertension Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002–2017
Figure 14: Hypertension Therapeutics Market, Global, Diseased Population (millions), 2002–2017
Figure 15: Hypertension Therapeutics Market, Global, Treatment-Seeking Population (millions), 2002–2017
Figure 16: Hypertension Therapeutics Market, Global, Diagnosis Population (millions), 2002–2017
Figure 17: Hypertension Therapeutics Market, Global, Prescription Population (millions), 2002–2017
Figure 18: Hypertension Therapeutics Market, Global, Market Segmentation by Geography (%), 2010 and 2017
Figure 19: Hypertension Therapeutics Market, Global, Market Segmentation by Geography ($bn), 2002–2017
Figure 20: PAH Therapeutics Market, Treatment Flow Algorithm for PAH, 2011
Figure 21: PAH Therapeutics Market, Global, Revenue Forecasts ($m), 2002–2017
Figure 22: PAH Therapeutics Market, Global, Annual Cost of Therapy ($), 2002–2017
Figure 23: PAH Therapeutics Market, Global, Treatment Usage Patterns (thousand), 2002–2017
Figure 24: PAH Therapeutics Market, Global, Diseased Population (thousand), 2002–2017
Figure 25: PAH Therapeutics Market, Global, Treatment-Seeking Population (thousand), 2002–2017
Figure 26: PAH Therapeutics Market, Global, Diagnosed Population (thousand), 2002–2017
Figure 27: PAH Therapeutics Market, Global, Prescription Population (thousand), 2002–2017
Figure 28: PAH Therapeutics Market, Global, Market Segmentation by Geography (%), 2010 and 2017
Figure 29: PAH Therapeutics Market, Global, Market Segmentation by Geography ($bn), 2002–2017
Figure 30: Anti-Hypertensives Market, Global, Market Share by Geography (%), 2010 and 2017
Figure 31: Anti-Hypertensives Market, Global, Revenue Forecasts by Geography ($bn), 2002–2017
Figure 32: Anti-Hypertensives Market, The US, Revenue Forecasts ($bn), 2002–2017
Figure 33: Anti-Hypertensives Market, The US, Annual Cost of Therapy ($), 2002–2017
Figure 34: Anti-Hypertensives Market, The US, Treatment Usage Patterns (millions), 2002–2017
Figure 35: Anti-Hypertensives Market, The US, Diseased Population (millions), 2002–2017
Figure 36: Anti-Hypertensives Market, The US, Treatment-Seeking Population (millions), 2002–2017
Figure 37: Anti-Hypertensives Market, The US, Diagnosed Population (millions), 2002–2017
Figure 38: Anti-Hypertensives Market, The US, Prescription Population (millions), 2002–2017
Figure 39: Anti-Hypertensives Market, Top Five Countries in Europe, Revenue Forecasts ($bn), 2002–2017
Figure 40: Anti-Hypertensives Market, Top Five Countries in Europe, Revenue Forecasts by Country, ($bn), 2002-2017
Figure 41: Anti-Hypertensives Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2002–2017
Figure 42: Anti-Hypertensives Market, Top Five Countries in Europe, Treatment Usage Patterns (millions), 2002–2017
Figure 43: Anti-Hypertensives Market, Top Five Countries in Europe, Diseased Population (millions), 2002–2017
Figure 44: Anti-Hypertensives Market, Top Five Countries in Europe, Treatment-Seeking Population (millions), 2002–2017
Figure 45: Anti-Hypertensives Market, Top Five Countries in Europe, Diagnosed Population (millions), 2002–2017
Figure 46: Anti-Hypertensives Market, Top Five Countries in Europe, Prescription Population (millions), 2002–2017
Figure 47: Anti-Hypertensives Market, Japan, Revenue Forecasts ($bn), 2002–2017
Figure 48: Anti-Hypertensives Market, Japan, Annual Cost of Therapy ($), 2002–2017
Figure 49: Anti-Hypertensives Market, Japan, Treatment Usage Patterns (millions), 2002–2017
Figure 50: Anti-Hypertensives Market, Japan, Diseased Population (millions), 2002–2017
Figure 51: Anti-Hypertensives Market, Japan, Treatment-Seeking Population (millions), 2002–2017
Figure 52: Anti-Hypertensives Market, Japan, Diagnosed Population (millions), 2002–2017
Figure 53: Anti-Hypertensives Market, Japan, Prescription Population (millions), 2002–2017
Figure 54: Anti-Hypertensives Market, Global, R&D Pipeline by Indication (%), 2011
Figure 55: Anti-Hypertensives Market, Global, R&D Pipeline by Phase (%), 2011
Figure 56: Anti-Hypertensives Market, Global, R&D Pipeline by Phase in Hypertension Market (%), 2011
Figure 57: Anti-Hypertensives Market, Global, R&D Pipeline by Phase in Pulmonary Arterial Hypertension Market (%), 2011
Figure 58: Anti-Hypertensives Market, Global, Market Share by Company (%), 2010
Figure 59: Anti-Hypertensives Market, Global, SWOT – Novartis, 2011
Figure 60: Anti-Hypertensives Market, Global, SWOT – Merck, 2011
Figure 61: Anti-Hypertensives Market, Global, SWOT – Daiichi Sankyo, 2011
Figure 62: Anti-Hypertensives Market, Global, SWOT – Sanofi, 2011
Figure 63: Anti-Hypertensives Market, Global, SWOT – AstraZeneca, 2011
Figure 64: Anti-Hypertensives Market, Global, SWOT – United Therapeutics, 2011
Figure 65: Anti-Hypertensives Market, Global, SWOT – Actelion Ltd, 2011
Figure 66: Anti-Hypertensives Market, Global, SWOT – Pfizer, 2011
Figure 67: Anti-Hypertensives Market, Global, Deals by Type (%), 2005–2011
Figure 68: Anti-Hypertensives Market, Global, M&A Deals by Year, 2005–2011
Figure 69: Anti-Hypertensives Market, Global, M&A Deals by Geography, 2005–2011
Figure 70: Anti-Hypertensives Market, Global, Major Licensing Agreements by Indication (%), 2005–2011
Figure 71: Anti-Hypertensives Market, Global, Major Licensing Agreements by Phase (%), 2005–2011
Figure 72: Anti-Hypertensives Market, Global, Major Licensing Agreements by Geography (%), 2005–2011
Figure 73: GBI Research Market Forecasting Model
 
Research assistance
We can help you find what you need. Call us or write us:
US: 800.298.5699
Int'l: +1.240.747.3093
Need help in your search?
 
Related Markets

Prescription Drugs Reports
 
 

Share this report


Other tasks

 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!